Pembrolizumab (Pembro) vs Standard-of-Care (SOC) in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): 6-Year Follow-Up of KEYNOTE-040
Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pembrolizumab (Pembro) vs Standard-of-Care (SOC) in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): 6-Year Follow-Up of KEYNOTE-040 ### Output: Pembrolizumab